Corporate News
Verici Dx plc (VRCI.L) recorded a flat 0 % movement over a 24‑hour period concluding at 05:04 AM Central Europe on Friday, 23 November 2026. At the close, one share of Verici Dx traded for approximately £0.23 on the London Stock Exchange. The company’s current share supply stands at 40.6 million, while its market capitalisation is £12.5 million. In the last 24 hours, roughly £2.3 million worth of Verici Dx shares changed hands.
Recent Performance
Since the end of last month, Verici Dx’s stock has risen by 4.55 %. Its simple moving average over the preceding 200 days is positioned at £0.43. The most recent 52‑week high reached £0.98 on 12 May 2025, whereas the 52‑week low fell to £0.00 on 10 February 2026, indicating a tight trading range for the near‑future.
Peer Activity
The company’s performance can be contextualised by the movements of several comparable stocks in the past 24 hours:
| Stock | 24‑hr Change | Current Price | Market Capitalisation | P/E Ratio |
|---|---|---|---|---|
| Airea (AIEA.L) | +1.92 % | £26.50 | £14.6 million | 7.67 |
| First Class Metals (FCM.L) | 0 % | £2.50 | £14.8 million | — |
| Arcontech (ARC.L) | 0 % | £81.00 | £14.7 million | 13.14 |
| Orcadian Energy (ORCA.L) | +12.5 % | £15.50 | £14.8 million | — |
| Aptamer (APTA.L) | +3.23 % | £0.32 | £14.6 million | — |
Airea and Orcadian Energy exhibit modest upward momentum, whereas Verici Dx remains unchanged, reflecting a period of market consolidation.
Company Overview
Verici Dx plc is headquartered in Cardiff, United Kingdom, and operates within the healthcare sector with a focus on immuno‑diagnostics. The firm develops tests that assess patient responses following organ transplants, providing critical information for transplant management. Verici Dx’s client base is confined to the United Kingdom, and its shares trade exclusively on the London Stock Exchange. For further details, the company’s website can be accessed at www.vericidx.com .
